Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.49M | -56.22M | -54.30M | -58.24M | -62.80M |
| Total Depreciation and Amortization | 1.59M | 1.63M | 1.70M | 1.64M | 1.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.24M | 8.31M | 6.14M | 6.44M | 6.87M |
| Change in Net Operating Assets | 16.50M | 32.95M | 67.57M | 31.78M | 36.57M |
| Cash from Operations | -17.15M | -13.33M | 21.10M | -18.38M | -17.65M |
| Capital Expenditure | -429.00K | -438.00K | -58.00K | -36.00K | -30.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -429.00K | -438.00K | -58.00K | -36.00K | -30.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -7.00K | -28.00K | -3.38M | -5.07M |
| Issuance of Common Stock | 13.08M | 13.08M | 33.10M | 32.58M | 24.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.03M | 47.32M | -- | -- | -- |
| Cash from Financing | 60.11M | 60.39M | 33.07M | 29.20M | 19.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.53M | 46.63M | 54.12M | 10.78M | 1.68M |